Hansa Biopharma — Oktober 2024
-
Hansa Biopharma: NiceR is in a good position to expand the future market
-
Hansa's next-gen IgG degrader shows promise, sparks stock rally https://firstwordpharma.com/story/5901548
-
Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Result (17 Oct 2024, 07:00)
-
"The ConfIdeS trial continues to progress following completed randomization in May and data from the study is expected to provide the basis for a Biologics License Application (BLA) with the US Food and Drug Administration (FDA) in the second half of 2025."
-
"Conference Call Details
Hansa Biopharma will host a telephone conference today Thursday, October 17, 2024, at 14:00 CET / 8:00 am ET.
The event will be hosted by Søren Tulstrup, President and CEO, Evan Ballantyne, CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim results and a business and pipeline update. It will be held in English."
-
Ifg. "Consensus model Total" herfra: (Analysts and consensus) https://www.hansabiopharma.com/investors/analysts/ rammer i vi oppe i intervallet mellem Median-High for 2024. Overslag: Revenue 188.6 (9M 2024) + 78.4 (Q4 2024 gæt) = 267 MSEK. Det er altså rigtigt fint.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind